&nbsp;Value of four biological factors in the evaluation of neoadjuvant chemotherapy for locally advanced breast cancer

doi:10.16098/j.issn.0529-1356.2019.03.011

PDF(4269 KB)

Acta Anatomica Sinica ›› 2019, Vol. 50 ›› Issue (3) : 329-333. DOI: 10.16098/j.issn.0529-1356.2019.03.011

Cancer Biology

Value of four biological factors in the evaluation of neoadjuvant chemotherapy for locally advanced breast cancer

GU Bei GUO Bin* SHI Guo-jian LI Hui-hua ZHANG Jie

Author information +

History +

Abstract

To explore the value of p53, Ki67, nm23 and epidermal growth factor receptor (EGFR) in the evaluation of the efficacy of neoadjuvant chemotherapy for locally advanced breast cancer. Methods From January 1, 2013 to March 31, 2018, 98 cases of locally advanced breast cancer in our hospital were selected as the research subjects. The changes of p53, Ki67, nm23 and EGFR before and after neoadjuvant chemotherapy and their relationship with clinical efficacy were detected. Results The positive expression of p53, Ki67 and EGFR after chemotherapy were all lower than those before chemotherapy, and the positive expression of nm23 was higher than that before chemotherapy, the difference was statistically significant (P<0.05). The effective rate of p53 positive was lower than that of the negative ones, and the difference was statistically significant (P<0.05). The effective rates of Ki67 and nm23 positive were higher than that of negative ones, and the difference was statistically significant (P<0.05). There was no statistical difference in effective rate between the positive EGFR and negative ones (P>0.05). Conclusion Neoadjuvant chemotherapy can significantly improve the expression of biological factors p53, Ki67, EGFR and nm23 in locally advanced breast cancer patients, and p53, Ki67 and nm23 have certain value in evaluating the curative effect of chemotherapy.

Key words

Breast cancer / p53 / ki67 / nm2 / Epidermal growth factor receptor / Neoadjuvant chemotherapy / Human

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations

GU Bei GUO Bin, SHI Guo-jian LI Hui-hua ZHANG Jie. Value of four biological factors in the evaluation of neoadjuvant chemotherapy for locally advanced breast cancer[J]. Acta Anatomica Sinica. 2019, 50(3): 329-333 https://doi.org/10.16098/j.issn.0529-1356.2019.03.011

References

［1］ Yao LSh, Yuan YL, Li Y, et al. Construction of eukaryotic expression vector of PinX1 gene and its expression in breast cancer cells［J］. Practical Geriatrics, 2015,29(12):1000-1003. (in Chinese)

姚乐申，袁毅路，李燕, 等. PinX1基因的真核表达载体构建及其在乳腺癌细胞中的表达［J］. 实用老年医学,2015,29(12):1000-1003.

［2］ Hu GW, Wang JD, Zhao ChY. Effect of acupuncture on the first WBC reduction after chemotherapy for breast cancer［J］. Beijing Traditional Chinese Medicinem, 2015,35(8):777-779. (in Chinese)

胡高武，王建东，赵春英. 针刺治疗对乳癌化疗后首次WBC减少症的影响［J］. 北京中医药,2015,35(8):777-779.

［3］ Broglio KR, Quintana M, Foster M, et al. Association of pathologic complete response to neoadjuvant therapy in HER2-Positive breast cancer with longterm outcomes: a meta-analysis［J］. JAMA Oncol,2016,2(6):751-760.

［4］ Li Z, Heng J, Yan J, et al. Integrated analysis of gene expression and methylation profiles of 48 candidate genes in breast cancer patients［J］. Breast Cancer Res Treat,2016,160(2):371-383.

［5］ Leo F, Bartels S, Magel L, et al. Prognostic factors in the myoepithelial-like spindle cell type of metaplastic breast cancer［J］. Virchows Arch,2016,469(2):191-201.

［6］ Zhang ChL, Li H, Li JP. Expression of p53, Ki67, EGFR, Nm23 in breast cancer and their correlations with clinical prognosis ［J］. Hainan Medical Journal,2014,25(1):15-17. (in Chinese)

张朝林，李宏，李金平. p53、Ki67、EGFR、Nm23在乳腺癌组织中的表达及临床意义［J］. 海南医学,2014,25(1):15-17.

［7］ Zhang L, Varma NR, Gang ZZ, et al. Targeting triple negative breast cancer with a small-sized paramagnetic nanoparticle［J］. J Nanomed Nanotechnol,2016,7(5):4172-4180.

［8］ Chen AX, Yu Y, Meng R, et al. he predictive value of tumor-infiltrating lymphocytes in patients with breast cancer treated with neoadjuvant chemotherapy［J］. Chinese Journal of Clinical Oncology, 2017,44(23):1184-1188. (in Chinese)

陈翱翔，余岳，孟然，等. 肿瘤浸润淋巴细胞比例对乳腺癌新辅助化疗疗效的预测作用［J］. 中国肿瘤临床,2017,44(23):1184-1188.

［9］ Yang LX. Clinical efficacy of paclitaxel and platinum in patients with advanced breast cancer and their effects on HER-2 and EGFR［J］. Guide of China Medicine, 2017,15(31):129-130. (in Chinese)

杨丽娴. 乳腺癌晚期患者应用紫杉醇与铂类的临床治疗效果及对HER-2、EGFR的影响研究［J］. 中国医药指南,2017,15(31):129-130.

［10］Yu HY, Li WP, Gao HY, et al. Relationship between the pathological assessment levels of neoadjuvant chemotherapy and the expressions of Ki67 and P53 in breast cancer. ［J］. Chinese Journal of Breast Disease(Electronic Version), 2011,05(3):297-305. (in Chinese)

余海云，李文萍，郜红艺，等. 新辅助化疗疗效与乳腺癌Ki67、P53表达的关系［J］. 中华乳腺病杂志（电子版）,2011,05(3):297-305.

［11］Yang Y, Wei ShZh, Du YX, et al. Expression of p53,Ki-67 and PCNA in esophageal squamous cell carcinoma and correlation with radiotherapy effect and prognosis［J］. Journal of Southeast University(Medical Science Edition), 2017,36(2):155-161. (in Chinese)

杨艳，韦淑贞，杜云翔，等. p53、Ki-67、PCNA的表达与食管鳞癌放疗近期疗效及预后的关系［J］. 东南大学学报（医学版）,2017,36(2):155-161. 

［12］ Wang L, Yu X, Li J, et al. Prognostic significance of p53 expression in patients with esophageal cancer: a metaanalysis［J］. BMC Cancer,2016,16:373.

［13］Cui HB, Ge HE，Bai XY, et al. Application of the predictors EGFR, HER2, Ki-67 and P53 on neoadjuvant chemotherapy in patients with advanced gastric cancer［J］. China Medical Herald, 2014,11(2):35-38. (in Chinese)

崔海滨，葛怀娥，白希永，等. EGFR、HER2、Ki-67、P53在进展期胃癌新辅助化疗疗效预测中的应用［J］. 中国医药导报,2014,11(2):35-38.

［14］Wang HM, Zhang H, Zhang JX. Effect of neoadjuvant chemotherapy on expression of ER PR P53 c-erb-B-2 Ki-67 in breast cancer patients［J］. Anhui Medical Journal, 2014,35(6):724-726. (in Chinese)

王红梅，张晖，张京雪. 新辅助化疗对乳腺癌患者ER PR P53 c-erb-B-2 Ki-67表达的影响［J］. 安徽医学,2014,35(6):724-726.

［15］Ning DB, Zhao YZh, Qi HH. Expression and significance of VEGF and nm23 in primary breast cancer and lymph node metastases［J］. Shandong Medical Journal, 2014,54(35):16-18. (in Chinese)

宁殿宾，赵玉哲，祁红辉. 乳腺癌原发灶和淋巴结转移灶中VEGF、nm23的表达变化及意义［J］. 山东医药,2014,54(35):16-18.

［16］Chen J. Expression of human epidermal growth factor receptor-2, tumor suppressor gene, estrogen receptor and progesterone receptor in elderly women with breast cancer and their clinical treatment［J］. Chinese Journal of Gerontology, 2016,36(9):2181-2183. (in Chinese)

陈军. 老年女性乳腺癌患者人表皮生长因子受体-2、抑癌基因、雌激素受体和孕激素受体表达情况及临床治疗［J］. 中国老年学杂志,2016,36(9):2181-2183.

［17］Wang XY, Zhang WW, Shi XJ, et al. Expressions of VEGF,EGFR and Smad4 in breast cancer tissue and their relationship with lymphatic metastasis［J］. International Journal of Laboratory Medicine,2017,38(23):3300-3302. (in Chinese)

王晓英，张卫卫，施先君，等. 乳腺癌组织中VEGF、EGFR和Smad4的表达及其与淋巴结转移的关系分析［J］. 国际检验医学杂志,2017,38(23):3300-3302.